SCHEMBL4085409

SCHEMBL4085409

COC(=O)c1ccc(OCCN2C(=O)CCCN2CCC(=O)Cc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 2/20 0.43
PTGER2 P43116 2/20 0.43
MAOB P27338 3/20 0.43
NR4A2 P43354 1/20 0.41
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
LTA4H P09960 1/20 0.38
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
KCNN4 O15554 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
HTR2A P28223 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087532 0.93 MAOB (0.44) PTGER4PTGER2MAOBNR4A2KDM4E
SCHEMBL4087358 0.90 PTGER4 (0.55) PTGER4PTGER2KDM4EKMT2AMEN1
SCHEMBL4087365 0.88 PTGER4 (0.49) PTGER4PTGER2KDM4EKMT2AMEN1
SCHEMBL4077231 0.86 PTGER4 (0.61) PTGER4PTGER2MAOBNR4A2CTSD
SCHEMBL4087328 0.85 PTGER4 (0.44) PTGER4PTGER2KDM4EKMT2AMEN1
SCHEMBL4081988 0.82 PTGER4 (0.40) PTGER4PTGER2KMT2AMEN1LMNA
SCHEMBL27717957 0.80 KMT2A (0.47) PTGER4PTGER2KDM4EKMT2AMEN1
SCHEMBL4077453 0.80 KMT2A (0.42) PTGER4PTGER2KDM4EKMT2AMEN1
SCHEMBL4086039 0.80 PTGER4 (0.42) PTGER4PTGER2KDM4EKMT2AMEN1
SCHEMBL4084927 0.79 PTGER4 (0.42) PTGER4PTGER2KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847533-B1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-14 EP disclosed
US-7531533-B2 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-05-12 US disclosed
EP-1847533-A1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF Asahi Kasei Pharma Corporation (JP) 2007-10-24 EP disclosed
US-20070060590-A1 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060590-A1 6-Membered heterocyclic compound and use thereof WNT1, CYP11B2, CYP11B1 PTGER4 33/4885PTGER2 39/4885MAOB 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.